New Drugs in the Pipeline for the Treatment of HIV: a Review (Q45067800)

9 December 2017

New Drugs in the Pipeline for the Treatment of HIV: a Review (English)

1 reference

9 December 2017

Leigh Anne Hylton Gravatt

1

1 reference

9 December 2017

Crystal R Leibrand

2

1 reference

9 December 2017

Sulay Patel

3

1 reference

9 December 2017

MaryPeace McRae

4

1 reference

9 December 2017

19 September 2017

1 reference

Current infectious disease reports

9 December 2017

1 reference

9 December 2017

19

1 reference

9 December 2017

42

1 reference

9 December 2017

11

1 reference

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects

9 December 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Latency reversal and viral clearance to cure HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Erasers of histone acetylation: the histone deacetylase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Targeting Class I Histone Deacetylases in a "Complex" Environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Panobinostat in lymphoid and myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Peginterferon α-2a for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-017-0601-X

Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF

21 January 2018

1 reference

12 December 2020

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

1 reference

12 December 2020

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study

1 reference

12 December 2020

Current views on interferon therapy for HIV.

1 reference

12 December 2020

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

1 reference

12 December 2020

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial

1 reference

12 December 2020

10.1007/S11908-017-0601-X

Identifiers

DOI

1 reference

9 December 2017

1 reference